Nurexone Biologic Inc · TSXV:NRX
Nurexone Biologic — Investor Presentation (2025)
17 slides from Nurexone Biologic's investor presentation, 2025
Slide 1: Where Nature Ends, NurExone Begins
Where Nature Ends, NurExone Begins Transforming Regenerative Medicine Q4 2025 | Canada (TSXV: NRX) Germany (FRA: J90.F) US (OTCQB: NRXBF)
Slide 2: Disclaimer
DISCLAIMER Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction. This presentation contains “forward-looking information” for purposes of applicable securities laws
Slide 3: All scientists agree that the best way to restore function after spinal cord injury
[Christopher] Reeve-Irvine Research Center (RIRC) : “All scientists agree that the best way to restore function after spinal cord injury is to find ways to regenerate the [neural] connections that are broken ”1 https://www.reeve.uci.edu/research/regeneration-to-reverse-paralysis 3
Slide 4: Company Overview
SINCE ITS INCEPTION, COMPANY OVERVIEW NUREXONE HAS RAISED US$~20M Founded in 2020, NurExone trades on the TSX Venture Canada (TSXV: NRX), Germany (FRA: J90.F) US (OTCQB: NRXBF) Founders 25% Key assets: Shareholder Technology: 5 patent families 2 already granted in US and ● Ownership * other key terr
Slide 5: Corporate Structure
CORPORATE STRUCTURE 100% 100% NurExoneBiologic Inc [TSXV:”NRX”,OTCQB:”NRXBF”,GER:”J90] NurExone Biologic Ltd ExoTop – Cells & Exosomes [Israeli Private Company] [USA Private Company] • R&D • Naïve Exosome Production • Product Development • Naïve Exosome Supply • Product Production (Sales logistics a
Slide 6: Addressing Multi-Billion Dollar Global Markets with Unmet Medical Needs
ADDRESSING MULTI-BILLION DOLLAR GLOBAL MARKETS WITH UNMET MEDICAL NEEDS NurExone’s first two Central Nervous System indications 1 Acute Spinal Cord Injury (SCI) 2 Glaucoma - Acute Glaucoma “There is currently no way to repair a damaged or bruised “There is no cure (yet) for glaucoma”4, Current spina
Slide 7: ExoPTEN: Acute Spinal Cord Injury
ExoPTEN: Acute Spinal Cord Injury Preclinical Data Suggests Potential to Heal Transected spinal cord (rat) 2 weeks post internasal ExoPTEN treatment Damaged Neurons and Restore Motor Function ◉ Short cycles of NurExone's regenerative ExoPTEN therapy administered intranasally, led to significant moto
Slide 8: ExoPTEN: Glaucoma
Optic Nerve Cell Survival ExoPTEN: GLAUCOMA (Retinal Ganglion Cells) Preclinical Data Suggests Optic Nerve Healing and Vision Restoration 15 10 5 uV 0 -5 -10 A-left side-normal, B-middle-damaged, C-right side-after treatment, 0 9.5 28.5 47.5 66.5 85.5 114 133 152 171 190 209 228 247 218.5 19 38 57 7
Slide 9: Pipeline
Pipeline Cutting Edge ExoTherapy Development to Recover Lost Function A single process serving multiple high-value indications 9
Slide 10: How Do We Do It? Harnessing the Regenerative Power of Exosomes
HOW DO WE DO IT? HARNESSING THE REGENERATIVE POWER OF EXOSOMES Nature’s “Guided Missiles” Targeting Inflammation ◉ Exosomes are naturally occurring nanoparticles with healing and “homing” capabilities ◉ We use MSC exosomes as “guided missiles” to deliver therapeutic cargo Exosomes as drug delivery ◉
Slide 11: Commercialization: Multi-Layered Revenue Strategy
COMMERCIALIZATION: MULTI-LAYERED REVENUE STRATEGY Potential Revenue Streams Product/Technology Main Focus: ExoPTEN for Acute Spinal Cord Injury - leading product with accelerated “time to market” strategy ExoPTEN for Optic Nerve Regeneration – leading product with high potential for out-licensing st
Slide 12: Product Road Map
PRODUCT ROAD MAP Clear Path towards Clinical Trials Plans for FDA and EMA approvals and a near term human clinical trial Q1 2023 H1 2023 Q4 2023 H1 2024 On-going 2025 H2 2026 H1 2027 Establish scaled up Finalize product ODD Approval Preclinical OMPD Approval IND submission Phase I/IIa SCI ExoPTEN Pr
Slide 13: Experienced Leadership Team
EXPERIENCED LEADERSHIP TEAM Dr. Lior Shaltiel Mr. Eran Ovadya Mr. Yoram Drucker Dr. Tali Kizhner Dr. Ina Sarel Chief Executive Officer Chief Financial Officer Founder, VP Strategic R&D Director Head of CMC, & Director A professional track record from Development & Chairman Over 15 years of R&D and C
Slide 14: Seasoned Board of Directors
SEASONED BOARD OF DIRECTORS Israel Canada Dr. Gadi Riesenfeld Dr. Lior Shaltiel Yoram Drucker Oded Orgil, LL.B. James (Jay) Richardson Director Chief Executive Officer Founder, VP Business Development Director Director & Active Chairman of the Board Dr. Riesenfeld has served on An entrepreneur and S
Slide 15: Expert Scientific Advisory Board
EXPERT SCIENTIFIC ADVISORY BOARD Prof. Teodoro Forcht Dagi, MD, MPH Prof. Gabriel Zeilig, MD Prof. Michael Belkin, MD neurosurgeon who serves as distinguished scholar and Prof. Gabi Zeilig is the director of the Department of Prof. Belkin was the founder of the Eye Research professor at Queen’s Univ
Slide 16: NurExone Biologic - Summary
NUREXONE BIOLOGIC - SUMMARY Regenerating Nerves and Recovering Lost Function ExoTherapy platform harnesses exosomes to deliver targeted therapies for a diverse range of diseases- a promising therapeutic approach with significant commercial potential. Two clinical programs targeting areas with a high
Slide 17: Thank You
TSXV: NRX | TSXV: NRX | OTCQB: NRXBF THANK YOU For more information please contact: info@nurexone.com DISCLOSURE The matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the company could differ significa